Autologous CAR T-cell therapy in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor targeting GPRC5D; upon antigen engagement, CAR signaling (CD3ζ with co-stimulation) activates T cells to proliferate and kill GPRC5D-expressing myeloma cells.
Autologous T cells are engineered to express a chimeric antigen receptor targeting GPRC5D; upon antigen binding, CD3ζ and co-stimulatory signaling activate and expand the T cells, driving cytokine release and perforin/granzyme-mediated killing of GPRC5D-positive myeloma cells.
YES
DIRECT
CAR T cells recognize GPRC5D on target cells, activate via CD3ζ/costimulatory signaling, and kill through perforin/granzyme-mediated cytolysis and apoptosis.
Murine IgG1 monoclonal antibody against CA125 (MUC16); forms immune complexes with tumor-associated and circulating CA125 to enhance dendritic cell antigen uptake and elicit CA125-specific T- and B-cell responses; can mediate Fc-dependent effector functions (ADCC/complement).
Murine IgG1 monoclonal antibody against CA125 (MUC16) that binds tumor-associated and circulating CA125 to form immune complexes, enhancing dendritic cell uptake and presentation to elicit CA125-specific T- and B-cell responses; can also trigger Fc-mediated effector functions (ADCC and complement).
YES
DIRECT
IgG1 antibody binds CA125 (MUC16) on tumor cells and engages Fc effector functions to mediate NK-cell ADCC and complement-dependent cytotoxicity.
Murine IgG1 monoclonal antibody against CA125 (MUC16); forms immune complexes with tumor-associated and circulating CA125 to enhance dendritic cell antigen uptake and elicit CA125-specific T- and B-cell responses; can mediate Fc-dependent effector functions (ADCC/complement).
Murine IgG1 monoclonal antibody against CA125 (MUC16) that binds tumor-associated and circulating CA125 to form immune complexes, enhancing dendritic cell uptake and presentation to elicit CA125-specific T- and B-cell responses; can also trigger Fc-mediated effector functions (ADCC and complement).
NO
INDIRECT
Oregovomab coats CA125+ tumor cells; CD16a+ NK cells bind the Fc and mediate ADCC (and complement), killing the CA125+ cells. CD16a-expressing cells act as effectors, not targets.
Murine IgG1 monoclonal antibody against CA125 (MUC16); forms immune complexes with tumor-associated and circulating CA125 to enhance dendritic cell antigen uptake and elicit CA125-specific T- and B-cell responses; can mediate Fc-dependent effector functions (ADCC/complement).
Murine IgG1 monoclonal antibody against CA125 (MUC16) that binds tumor-associated and circulating CA125 to form immune complexes, enhancing dendritic cell uptake and presentation to elicit CA125-specific T- and B-cell responses; can also trigger Fc-mediated effector functions (ADCC and complement).
NO
INDIRECT
Oregovomab binds CA125 on tumor cells; Fc gamma receptor IIa (CD32a)-expressing immune cells engage its Fc to mediate ADCC/complement/phagocytosis against CA125+ tumor cells, not against CD32a+ cells.
Anti-CD22 antibody–drug conjugate delivering calicheamicin to induce DNA double-strand breaks in B-cell blasts.
Humanized anti-CD22 monoclonal antibody linked to calicheamicin; upon CD22 binding and internalization in B-cell blasts, the payload is released to bind the DNA minor groove and cause double-strand breaks, leading to apoptosis.
YES
DIRECT
The anti-CD22 ADC binds CD22, is internalized, and releases calicheamicin inside the cell, which binds the DNA minor groove to cause double-strand breaks and apoptosis.